研发投入低于同行、3年半销售费用超23亿,威高血净IPO将上会大考

第一财经
20 Feb

3年半时间,销售费用超23亿元,其中市场教育及调研活动合计7.76亿元,业务招待费2.29亿元。 在赴港上市无果后,山东威高血液净化制品股份有限公司(下称“威高血净”)转战沪市主板IPO,上市申请将于2月26日正式上会审议。此次赴A之行能否顺利也受到市场的关注。近年来,威高血净业绩增速有所放缓,带量采购政策对公司经营业绩的影响也受到监管关注。作为该公司业绩贡献主力,血液透析器和血液透析管路在部分...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10